Saltar al contenido
Merck

19-4497

Metronidazole

SAJ first grade, ≥99.0%

Sinónimos:

2-Methyl-5-nitroimidazole-1-ethanol

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño



About This Item

Fórmula empírica (notación de Hill):
C6H9N3O3
Número CAS:
Peso molecular:
171.15
EC Number:
207-136-1
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
611683
MDL number:
grade:
SAJ first grade
assay:
≥99.0%

Nombre del producto

Metronidazole, SAJ first grade, ≥99.0%

InChI key

VAOCPAMSLUNLGC-UHFFFAOYSA-N

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

SMILES string

CC1=NC=C([N+]([O-])=O)N1CCO

grade

SAJ first grade

assay

≥99.0%

form

solid

availability

available only in Japan

dilution

(for analytical testing)

mp

159-161 °C (lit.)

antibiotic activity spectrum

Gram-negative bacteria
parasites

mode of action

DNA synthesis | interferes

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Chemical structure: imidazole

pictograms

Health hazard

signalword

Danger

Hazard Classifications

Carc. 1B - Muta. 1B - STOT RE 2

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Dina Zandbergen et al.
Journal of periodontology, 84(3), 332-351 (2012-05-23)
The treatment of periodontitis frequently begins with a non-surgical phase that includes scaling and root planing (SRP) and, on occasion, the use of systemic antibiotics. The goal of this review is to systematically evaluate the data concerning the effect of
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico